Mannitol
drugOn this page
Also known as Aridol kitBronchitolCordycepic acidCrystalline mannitol extra-fineCrystalline mannitol fineCrystalline mannitol standardD-(-)-mannitolD-mannitolDiosmolE-421E421INS NO.421INS-421Isomalt impuritymannitol-Manna sugarManniteMannitol 200Mannitol 2080
Summary
Mannitol (CHEMBL689) is an approved small-molecule osmotic diuretic (ATC B05CX04); indicated across 38 conditions including brain edema and constipation disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: B05CX04 (+4 more)
- Indications: 38 conditions
- Clinical trials: 122
- Chemistry: 182.17 Da · C6H14O6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL689 |
| Name | Mannitol |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 6251 |
| ChEBI | CHEBI:16899 |
| ATC | B05CX04, B05BC01, A06AD16, R05CB16, V04CX04 |
| Molecular formula | C6H14O6 |
| Molecular weight | 182.17 |
| InChIKey | FBPFZTCFMRRESA-KVTDHHQDSA-N |
SMILES: C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O
IUPAC name: (2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
ChEBI definition: The D-enantiomer of mannitol.
Pharmacological roles (ChEBI): osmotic diuretic, sweetening agent, antiglaucoma drug, allergen, hapten.
Other ChEBI roles (chemical / environmental): metabolite, food bulking agent, food anticaking agent, food humectant, food stabiliser, food thickening agent, Escherichia coli metabolite.
Also known as: Aridol kit, Bronchitol, Cordycepic acid, Crystalline mannitol extra-fine, Crystalline mannitol fine, Crystalline mannitol standard, D-(-)-mannitol, D-mannitol, Diosmol, E-421, E421, INS NO.421
Patent coverage: 305,229 distinct patent families (952,151 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Lethal(3)malignant brain tumor-like protein 1, Prelamin-A/C.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
38 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| brain edema | 4 | MONDO:0006684 | EFO:1000845 |
| constipation disorder | 4 | MONDO:0002203 | HP:0002019 |
| acute kidney injury | 4 | MONDO:0002492 | MONDO:0002492 |
| cystic fibrosis | 4 | MONDO:0009061 | MONDO:0009061 |
| bronchiectasis | 3 | MONDO:0004822 | HP:0002110 |
| malaria | 3 | MONDO:0005136 | EFO:0001068 |
| toxic shock syndrome | 3 | MONDO:0001881 | EFO:0006834 |
| ciguatera fish poisoning | 3 | MONDO:0043230 | EFO:1001291 |
| congenital heart disease | 3 | MONDO:0005453 | EFO:0005207 |
| kidney cancer | 3 | MONDO:0002367 | MONDO:0002367 |
| brain injury | 3 | MONDO:0043510 | MONDO:0043510 |
| coronary artery disorder | 3 | MONDO:0005010 | EFO:0001645 |
| brain disorder | 3 | MONDO:0005560 | HP:0001298 |
| stroke disorder | 2 | MONDO:0005098 | EFO:0000712 |
| hypotensive disorder | 2 | MONDO:0005468 | EFO:0005251 |
| opiate dependence | 2 | MONDO:0005530 | EFO:0005611 |
| pulpitis | 2 | MONDO:0006937 | EFO:1001139 |
| obstructive sleep apnea syndrome | 2 | MONDO:0007147 | EFO:0003918 |
| severe acute respiratory syndrome | 2 | MONDO:0005091 | MONDO:0100096 |
| hearing loss disorder | 2 | MONDO:0005365 | EFO:0004238 |
| osteoarthritis, knee | 2 | MONDO:0005416 | EFO:0004616 |
| injury | 1 | MONDO:0021178 | EFO:0000546 |
| chronic obstructive pulmonary disease | 1 | MONDO:0005002 | EFO:0000341 |
| glioblastoma | 1 | MONDO:0018177 | EFO:0000519 |
| diabetic neuropathy | 1 | MONDO:0006626 | EFO:1000783 |
| intracranial hypertension | 1 | MONDO:0006810 | EFO:1000992 |
| chronic myeloid leukemia | 1 | MONDO:0011996 | EFO:0000339 |
| anaplastic oligodendroglioma | 1 | MONDO:0016696 | EFO:0002501 |
| central nervous system neoplasm | 1 | MONDO:0006130 | EFO:1000158 |
| brain cancer | 1 | MONDO:0001657 | MONDO:0001657 |
| subarachnoid hemorrhage | 1 | MONDO:0005099 | EFO:0000713 |
| glioma | 1 | MONDO:0021042 | MONDO:0003268 |
6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 122.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 37 |
| PHASE3 | 21 |
| PHASE2 | 20 |
| PHASE1/PHASE2 | 13 |
| PHASE4 | 11 |
| PHASE1 | 10 |
| PHASE2/PHASE3 | 7 |
| EARLY_PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06841406 | PHASE4 | RECRUITING | Budesonide as a Treatment for Functional Dyspepsia |
| NCT06884657 | PHASE4 | RECRUITING | Effect of Mannitol on Propofol Level |
| NCT00426192 | PHASE4 | UNKNOWN | Effects of Hemofiltration and Mannitol Treatment on Cardiopulmonary-Bypass Induced Immunosuppression |
| NCT00677664 | PHASE4 | UNKNOWN | Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation |
| NCT01642745 | PHASE4 | COMPLETED | Mannitol (Aridol) and Methacholine (Provocholine) Responsiveness |
| NCT02091180 | PHASE4 | COMPLETED | Mannitol Improves Cerebral Oxygen Saturation |
| NCT02386449 | PHASE4 | COMPLETED | A Study Comparing Picoprep With Mannitol and Bisacodyl for Colon Cleansing in Preparation for Colonoscopy |
| NCT02677623 | PHASE4 | COMPLETED | Evaluation of Ureteral Patency in the Post-indigo Carmine Era |
| NCT02760862 | PHASE4 | COMPLETED | Comparative Study Between Hydrocortisone and Mannitol in Treatment of Postdural Puncture Headache |
| NCT03573999 | PHASE4 | COMPLETED | Effect of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation |
| NCT04534465 | PHASE4 | COMPLETED | Study to Gather Information on the Acceptability of a New Flavor System With Increasing Levels of 2, 4, 6 g or Higher of Mannitol for PEG 3350 in Subjects Having Infrequent Bowel Movements. |
| NCT04217421 | PHASE3 | RECRUITING | Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass |
| NCT06473779 | PHASE3 | ACTIVE_NOT_RECRUITING | Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. |
| NCT06914310 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Memantine as an Additive Therapy in Patients With Traumatic Brain Injury |
| NCT00113854 | PHASE3 | UNKNOWN | Mannitol as Adjunct Therapy for Childhood Cerebral Malaria |
| NCT00189007 | PHASE3 | UNKNOWN | Antenatal Allopurinol During Fetal Hypoxia |
| NCT00277537 | PHASE3 | COMPLETED | Safety and Efficacy of Bronchitol in Bronchiectasis |
| NCT00319345 | PHASE2/PHASE3 | TERMINATED | Sodium-Lactate and Traumatic Brain Injury |
| NCT00446680 | PHASE3 | COMPLETED | Long Term Administration of Inhaled Dry Powder Mannitol In Cystic Fibrosis - A Safety and Efficacy Study |
| NCT00630812 | PHASE3 | COMPLETED | Long Term Administration of Inhaled Mannitol in Cystic Fibrosis |
| NCT00669331 | PHASE3 | COMPLETED | Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis |
| NCT01028339 | PHASE3 | TERMINATED | Mannitol vs HS to Treat ICHT After Severe TBI : Comparison on PtiO2 and Microdialysis Values |
| NCT01111682 | PHASE3 | TERMINATED | Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure |
| NCT01142505 | PHASE3 | COMPLETED | Wheeze and Intermittent Treatment |
| NCT01606787 | PHASE3 | COMPLETED | Mannitol Use During Partial Nephrectomy Prior to Renal Ischemia and Impact on Renal Function Outcomes |
| NCT02134353 | PHASE3 | COMPLETED | A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects |
| NCT02196142 | PHASE3 | COMPLETED | Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence |
| NCT02570971 | PHASE3 | UNKNOWN | Mannitol Versus Supportive Care in Ciguatera Fish Poisoning |
| NCT02705573 | PHASE3 | COMPLETED | Effects of Mannitol on Delayed Graft Function After Cadaveric Renal Transplantation |
| NCT03162653 | PHASE3 | UNKNOWN | Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome |
| NCT03505489 | PHASE3 | COMPLETED | The Effect of Deep Inhalation on Mannitol Responsiveness |
| NCT04251689 | PHASE2/PHASE3 | COMPLETED | The Effect of Intravenous Mannitol Plus Saline on the Prevention of Cisplatin-induced Nephrotoxicity: A Randomized, Double-blind, Placebo Controlled Trial |
| NCT04385264 | PHASE2/PHASE3 | WITHDRAWN | #StayHome: Early Hydroxychloroquine to Reduce Secondary Hospitalisation and Household Transmission in COVID-19 |
| NCT04394143 | PHASE2/PHASE3 | COMPLETED | Effect of AD128 to Treat Obstructive Sleep Apnea |
| NCT04428372 | PHASE2/PHASE3 | COMPLETED | MAnnitol for Blood Pressure Stability in HemoDialysis (MAP-HD) |
| NCT04488874 | PHASE3 | COMPLETED | Sodium Lactate and Brain Relaxation (LSD) |
| NCT04870073 | PHASE3 | WITHDRAWN | Retrograde Autologous Priming and Mannitol for Reducing Hemodilution in Cardiac Surgery |
| NCT06846307 | PHASE3 | COMPLETED | The Effect of Mannitol Volume with Changes in Osmolarity in Traumatic Brain Injury |
| NCT07064720 | PHASE2/PHASE3 | COMPLETED | Adding Dexmedetomidine to Mannitol to Attenuate the Increase of Intracranial Pressure |
| NCT02800486 | PHASE2 | RECRUITING | Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).